Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
293 cells were transfected with anti-MSLN-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Mesothelin (296-580), Fc Tag (Cat. No. MSN-HF25x, 0.3 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-MSLN-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Mesothelin (296-580), Fc Tag (Cat. No. MSN-HF25x).
can bind Human MS4A1 / CD20 Full Length Protein, His Tag (Cat. No. CD0-H55Ha)with an affinity constant of 1.21 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind GFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HG2P4) with an affinity constant of 0.542 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| iCasp9M28z | iCasp9M28z | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Mesothelioma; Breast Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Neoplasms; Mesothelioma | Details |
| ATA-2271 | ATA-2271 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics | Mesothelioma | Details |
| MCY-M11 | MCY-M11 | Phase 1 Clinical | Maxcyte | Ovarian Neoplasms; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
| BMS-986148 | BMS-986148 | Phase 2 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 2 Clinical | Bayer Ag, Morphosys | Ovarian Neoplasms; Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| KD-021 (Nanjing KAEDI Biotech) | KD-021 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Neoplasms | Details |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details | |
| Anti-mesothelin CAR-T (Legend) | Phase 1 Clinical | Ovarian Neoplasms | Details | ||
| Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) | Details | ||||
| anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase 1 Clinical | Bayer Ag | Ovarian Neoplasms; Mesothelioma | Details |
| Amatuximab | MORAb-009; MORAB-009-006 | Phase 2 Clinical | National Cancer Institute | Ovarian Neoplasms; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| ABBV-428 | ABBV-428; ABBV428 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
| Anti-MESO CAR-T cell(Ruijin Hospital) | Phase 1 Clinical | Ruijin Hospital, Shanghai Jiaotong University School Of Medicine | Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
